'A done deal': FDA advisory committee votes unanimously against efficacy data for OTC nasal decongestant
Members of an FDA advisory committee on Tuesday voted unanimously against the efficacy of an over-the-counter nasal decongestant that’s been on the US market for more than 75 years.
The FDA called upon the Nonprescription Drugs Advisory Committee to weigh in on new data on oral phenylephrine, an ingredient in popular products such as Mucinex and Benadryl. Members voted 16-0 that data suggest the medication is not effective at the currently recommended 10 mg dose for nasal decongestion, and a majority agreed that they aren’t likely to be swayed by further research.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.